✦ LIBER ✦

Clinical outcome and predictors of survival in patients with pneumocystis jirovecii pneumonia - results of a tertiary referral centre

✍ Scribed by Roembke, Felicitas; Heinzow, Hauke Sebastian; Gosseling, Thomas; Heinecke, Achim; Domagk, Dirk; Domschke, Wolfram; Meister, Tobias

Book ID: 120687390
Publisher: Wiley (Blackwell Publishing)
Year: 2013
Tongue: English
Weight: 878 KB
Volume: 8
Category: Article
ISSN: 1752-6981
DOI: 10.1111/crj.12042

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mortality predictors of Pneumocystis jir

Mortality predictors of Pneumocystis jirovecii pneumonia in human immunodeficiency virus-infected patients at presentation: Experience in a tertiary care hospital of northern Taiwan

✍ Hsiao-Wei Wang; Cheng-Chih Lin; Chen-Feng Kuo; Chang-Pan Liu; Chun-Ming Lee 📂 Article 📅 2011 🏛 Scientific Communications 🌐 English ⚖ 167 KB

Differences in the clinical characterist

Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection

✍ Tatsuji ENOMOTO; Arata AZUMA; Ayumi KOHNO; Kazuyo KANEKO; Hitoshi SAITO; Minako 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

Cognitive and behavioural predictors of

Cognitive and behavioural predictors of survival in Alzheimer disease: results from a sample of treated patients in a tertiary-referral memory clinic

✍ Tom C. Russ; G. David Batty; John M. Starr 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

Pneumocystis jirovecii pneumonia in HIV-

Pneumocystis jirovecii pneumonia in HIV-negative patients: A prospective study with focus on immunosuppressive drugs and markers of immune impairment

✍ Roblot, France; Le Moal, Gwenael; Kauffmann-Lacroix, Catherine; Bastides, Freder 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 83 KB

Survival and complications in a cohort o

Survival and complications in a cohort of patients with anti-Delta positive liver disease presenting in a tertiary referral clinic

✍ Robert A. de Man; Renate P. Sprey; Hubert G.M. Niesters; Ruud A. Heijtink; Piete 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 679 KB

Predictors of adalimumab dose escalation

Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center

✍ Russell D. Cohen; Jeffrey R. Lewis; Hannah Turner; Laura E. Harrell; Stephen B. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Background: Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo for induction and maintenance of remission in moderate to severely active Crohn's disease (CD). Although the approved maintenance regimen in the U.S. is 40 mg subcutaneously every 14 days, some patients require